Orexo announces positive Phase III results for KW-2246 in Japan

27-Jul-2009 - Japan

Orexo’s partner in Japan, Kyowa Hakko Kirin, has obtained positive phase III results in Japan for KW-2246, which is approved for the treatment of breakthrough pain in cancer patients and marketed under the brand AbstralTM in Europe. Kyowa Hakko Kirin will now proceed with preparations for a new-drug application for KW-2246 in Japan for use in continuous pain management of acute cancer pain (breakthrough pain).

Orexo announced that Kyowa Hakko Kirin confirms that it has obtained positive clinical phase III results for KW-2246 in Japan. The clinical study results revealed a statistically significant difference between KW-2246 and the placebo, and clinical effectiveness was confirmed. In addition, with regard to safety, no unacceptable side effects were found during the clinical study period.

Kyowa Hakko Kirin will now proceed with the preparations for a new-drug application for KW-2246 in Japan.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances